- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib in locally advanced or metastatic breast cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 8, Pages 1177-1191
Publisher
Informa Healthcare
Online
2012-05-23
DOI
10.1517/13543784.2012.689824
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL)
- (2017) R. H. Huggins et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract 1054: S100B affects cell signaling in malignant melanoma
- (2012) Kira Gianni et al. CANCER RESEARCH
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reappraising antiangiogenic therapy for breast cancer
- (2011) Robert S. Kerbel BREAST
- Recent Developments in Treatment Stratification for Metastatic Breast Cancer
- (2011) Sarah Barton et al. DRUGS
- Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
- (2011) Harold J. Burstein JOURNAL OF CLINICAL ONCOLOGY
- Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies
- (2011) Marc Buyse et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial
- (2011) Ahmad Awada et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Changing End Points in Breast-Cancer Drug Approval — The Avastin Story
- (2011) Ralph B. D'Agostino NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer
- (2011) P. Gomez et al. ONCOLOGIST
- Synergistic activity of letrozole and sorafenib on breast cancer cells
- (2010) Mara A. Bonelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
- (2010) Claudine Isaacs et al. BREAST CANCER RESEARCH AND TREATMENT
- Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases
- (2010) Maximilian Merz et al. EUROPEAN JOURNAL OF CANCER
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of breast cancer with targeted agents: importance of heterogenicity
- (2010) Serena Di Cosimo et al. Nature Reviews Clinical Oncology
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
- (2009) Giulia Bianchi et al. ANTI-CANCER DRUGS
- Antiangiogenic Therapy for Metastatic Breast Cancer
- (2009) Arlene Chan DRUGS
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Care in India: The Current Scenario and the Challenges for the Future
- (2008) Gaurav Agarwal et al. Breast Care
- Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
- (2008) Q. Ding et al. CANCER RESEARCH
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
- (2008) Alvaro Moreno-Aspitia et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors
- (2008) L. Dal Lago et al. ONCOLOGIST
- Endpoints for Assessing Drug Activity in Clinical Trials
- (2008) R. Pazdur ONCOLOGIST
- Effective oral chemotherapy for breast cancer: pillars of strength
- (2007) M. Findlay et al. ANNALS OF ONCOLOGY
- Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy
- (2007) Ila Tamaskar et al. JOURNAL OF UROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now